Skin Hives Treatment Market is expected to reach USD 5.7 billion by 2031 | Top key players - Taiho Pharmaceutical, Galderma, Novartis AG.

Market Size and Growth:

The Global Skin Hives Treatment Market Size reached USD 2.6 billion in 2022 and is expected to reach USD 5.7 billion by 2031, growing with a CAGR of 10.5% during the forecast period 2024-2031. The Market is growing due to the rising prevalence of allergic skin conditions and increased awareness of effective treatments among patients. According to DataM Intelligence

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/skin-hives-treatment-market?sz

The Skin Hives Treatment Market encompasses products, therapies, and interventions designed to prevent, manage, or alleviate urticaria (hives) symptoms, including itching, redness, and swelling. It includes prescription drugs, over-the-counter medications, biologics, and natural remedies. The market focuses on improving patient quality of life, reducing flare-ups, and addressing both acute and chronic skin hives across diverse age groups.

Industry Recent Developments: United States

✅ September 2025: FDA approved Rhapsido (remibrutinib), the first oral targeted BTK inhibitor for chronic spontaneous urticaria, providing a new treatment option for patients not responding to antihistamines. The drug showed efficacy in reducing itching and hives in clinical trials and will be available in Q4 2025.

✅ October 2025: Despite recent FDA approvals, there remains a high unmet need in chronic spontaneous urticaria treatment, with two-thirds of physicians reporting gaps, which drives continued market innovation.

✅ October 2025: The chronic hives treatment landscape is evolving with increased emphasis on oral targeted therapies and improved access via teledermatology and online pharmacies, enhancing patient convenience.

Industry Recent Developments: Japan

✅ September 2025: Japan holds approximately 5.2% share of the global antipruritic market, with skin hives treatment growing steadily due to cultural emphasis on skincare and the integration of advanced technology like AI-driven diagnostic tools.

✅ October 2025: The chronic spontaneous urticaria market in Japan is expanding, supported by increased awareness of autoimmune-related hives and wider access to biologic therapies and immunosuppressants.

✅ November 2025: The aging population and strong healthcare infrastructure in Japan support growth in skin hives treatment, with a focus on minimally invasive and aesthetically beneficial therapies in alignment with local preferences.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/skin-hives-treatment-market?sz

Regulatory / FDA Approvals in 2025:

✅ On April 18, 2025, Dupixent (dupilumab) was approved by the U.S. FDA for adults and adolescents (12 yrs +) with CSU who remain symptomatic despite H1 antihistamine treatment.

✅ On September 30, 2025, Rhapsido (remibrutinib) was approved by the U.S. FDA as the first oral Bruton's tyrosine kinase (BTK) inhibitor for adult CSU patients who remain symptomatic despite H1 antihistamines.

Mergers, Acquisitions & Licensing in 2025:

✅ In March 2025, Novartis acquired exclusive worldwide rights to KRP‐M223 (developed by Kyorin Pharmaceutical) - a mast‐cell/MRGPRX2‐antagonist candidate for CSU and other allergic/inflammatory conditions - in a deal valued at approximately USD 830 million.

✅ Additional pipeline and licensing activity is evident: major companies are broadening CSU‐therapeutic portfolios, though detailed announced M&A beyond the above is limited for 2025.

Regulatory / Market Landscape Notes:

✅ The FDA "Novel Drug Approvals 2025" listed remibrutinib (Rhapsido) on 30 Sept 2025 for the indication of adult CSU refractory to antihistamines.

✅ Pipeline reports highlight that many CSU‐treatment candidates (e.g., targeting mast‐cells, basophils, BTK, MRGPRX2) were projected to file regulatory submissions in 2025, reflecting a vibrant late‐stage pipeline.

✅ The market for CSU treatments is expected to grow significantly driven by these approvals and pipeline launches.

Major Key Players:

Otsuka Pharmaceutical Co Ltd
Taiho Pharmaceutical
Amneal Pharmaceuticals
Galderma
F. Hoffmann-La Roche Ltd
Novartis AG
Dr. Reddy's Laboratories
Glenmark Pharmaceuticals
Genentech, Inc.
Sanofi SA.

Segments Covered in the Skin Hives Treatment Market:

By Type: Chronic Hives, Acute Hives.

By Treatment: Anti-Inflammatory Drugs, Anti-Itch Drugs, Antihistamines, Topical Steroids, Topical Anesthetics, Immunosuppressants, H2 Antagonists, Others.

By Route of Administration: Oral, Topical, Parenteral.

By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies.

Regional Analysis for Skin Hives Treatment Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=skin-hives-treatment-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Skin Hives Treatment market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Skin Hives Treatment Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Skin Hives Treatment market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Skin Hives Treatment Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Skin Hives Treatment market?

➠ Who are the global key manufacturers of the Skin Hives Treatment Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Skin Hives Treatment market opportunities and threats faced by the vendors in the global Skin Hives Treatment Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Skin Hives Treatment market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.